Intelligent Bio Solutions Inc

Intelligent Bio Solutions, Inc. operates as a biosensor diagnostic technology company. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions (NASDAQ: INBS ) stock is falling hard on Friday after the medical technology company announced details of a public share offering. With this news comes the pricing of the company's shares in this offering.

Why Is Intelligent Bio Solutions (INBS) Stock Down 52% Today?

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of an underwritten public offering of units (the “Units”) for gross proceeds of approximately $4.0 million.

Intelligent Bio Solutions Inc. Announces Pricing of $4,000,000 Underwritten Public Offering

International certification adds to Quality Management Systems credentials for the medical device industry and supports expansion plans into North America and Asia Pacific regions International certification adds to Quality Management Systems credentials for the medical device industry and supports expansion plans into North America and Asia Pacific regions

Intelligent Bio Solutions Obtains ISO Recertification for its Intelligent Fingerprinting Drug Screening Business

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful debut of its Intelligent Fingerprinting Drug Screening System at the 2023 Workplace Health & Safety Show in Sydney, Australia on September 20th and 21st. The non-invasive, portable system is designed to enable workplace health and safety managers to conduct simple, non-invasive workplace drug testing anytime and almost anywhere, serving as a deterrent against drug abuse and encouraging employees to adhere to health and safety policies.

Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia

New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting design phase and begin next stage of transfer to manufacture New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting design phase and begin next stage of transfer to manufacture

Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test

- Combined full-year revenue and government support income increased 355% year-over-year - - Received guidance from U.S. FDA on a regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge - - Granted 13 th patent following award of U.K. patent relating to DSR-Plus Cartridge Reader - - Recently secured 8 new customers just two months into product launch in Australia - NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal fourth quarter and full-year ended June 30, 2023, and provided a business update. “In the 2023 fiscal year, we maintained rapid expansion of our customer footprint, successfully entering the Australian market with accelerated uptake,” said Harry Simeonidis, President and Chief Executive Officer of Intelligent Bio Solutions.

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured 8 new customers across various locations throughout Australia, which collectively employ over 10,000 individuals, within just two months of launching its Intelligent Fingerprinting Drug Screening System in Australia.

Intelligent Bio Solutions Secures 8 New Customers with a Combined Workforce of Over 10,000 Employees Two Months into Product Launch in Australia

NEW YORK, July 06, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company developing and delivering intelligent, rapid, non-invasive testing solutions, today announced it has signed a distribution agreement for its Intelligent Fingerprinting Drug Screening System with Chile-based company TSCOM SPA, increasing the product's availability across South America. The Company further announced it received its first order under this agreement, coming from a Chile-based electrical distribution company.

Intelligent Bio Solutions Signs South American Distribution Agreement with TSCOM for Fingerprint Drug Screening System and Secures First Order

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received guidance from the U.S. Food and Drug Administration (the “FDA”) regarding the regulatory classification of its Intelligent Fingerprinting Drug Screening Cartridge. The FDA has provisionally determined that the cartridge falls within 21 CFR 862.3650, Opiate Test System, a Class II type device that requires the submission of a pre-market notification 510(k) and the FDA's clearance prior to marketing.

Intelligent Bio Solutions Receives Guidance from U.S. FDA on a Regulatory Pathway for Expansion into the United States for its Intelligent Fingerprinting Drug Screening Cartridge

Grant Funding received to date from the Australian Federal Government totals USD $3.25 million Grant Funding received to date from the Australian Federal Government totals USD $3.25 million

Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million

New York, New York--(Newsfile Corp. - May 24, 2023) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that management will be participating in the LD Micro Invitational XIII in Los Angeles, June 6-8, 2023. LD Micro Invitational XII – Presentation Details Date: Tuesday, June 6, 2023 Time: 9:30 a.m.

Intelligent Bio Solutions to Participate in the LD Micro Invitational XIII on June 6th

- Combined revenue and government support income increased 199% year-over-year - - Sequential revenue growth of 28% - - Filed 513(g) submission with U.S. FDA for Intelligent Fingerprinting Drug Screening Cartridge - - Granted U.K. patent relating to DSR-Plus Cartridge Reader - - Completion of Milestone 7, key phase of biosensor platform development - NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update. “INBS delivered revenue growth during the third quarter and achieved several important milestones in line with our regional expansion plans,” said Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions.

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Third Quarter Financial Results and Operational Highlights

Company secures new distribution and office facility to scale distribution of its Intelligent Fingerprinting Drug Screening System and significantly expand its capacity to service customers Company secures new distribution and office facility to scale distribution of its Intelligent Fingerprinting Drug Screening System and significantly expand its capacity to service customers

Intelligent Bio Solutions Scales Reach Throughout Asia-Pacific Region with Addition of Sales Team in Australia, New Distribution Hub and Office Facility

“Having experienced urine drug testing myself, I know it's not a pleasant experience for anyone. So, when it came to selecting a drug screening approach for Dodman, it was clear that fingerprint testing was a major step forward for workplace drug testing.” – Chris Davies, Health and Safety Manager, Dodman

UK Food Processing Equipment Manufacturer Latest to Adopt Intelligent Bio Solutions' Portable Fingerprint Drug Testing Solution

Company's 13th patent granted strengthens protection for unique and proprietary Intelligent Fingerprinting point-of-care diagnostic drug screening technology Company's 13th patent granted strengthens protection for unique and proprietary Intelligent Fingerprinting point-of-care diagnostic drug screening technology

Intelligent Bio Solutions Secures UK Patent for Intelligent Fingerprinting DSR-Plus Cartridge Reader

“Deploying the latest Intelligent Fingerprinting reader unit has helped our HR team to increase random drug testing productivity thanks to its faster analysis capabilities”- Dan Clayton, HR Manager, A & F Sprinklers “Deploying the latest Intelligent Fingerprinting reader unit has helped our HR team to increase random drug testing productivity thanks to its faster analysis capabilities”- Dan Clayton, HR Manager, A & F Sprinklers

A & F Sprinklers Selects Intelligent Bio Solutions' Latest DSR-Plus Screening Unit to Support its Random Drug Screening Program

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that the Company has selected Human and Supplement Testing Australia ("HASTA"), Australia's largest independent sports drug testing laboratory, as its preferred drug testing specialist in Australia to complete lab-based confirmation testing for its Intelligent Fingerprinting System, which analyzes sweat to screen for recent drug use.

Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced the closing of its previously announced underwritten public offering of 654,990 shares of common stock and warrants to purchase up to 196,497 shares of its common stock at a combined public offering price of $3.90 per share of common stock and accompanying warrants, which included the full exercise of the underwriter's option to purchase up to 85,430 additional shares of common stock and additional warrants to purchase up to 25,629 shares of its common stock. Including the option exercise, the aggregate gross proceeds from the offering were approximately $2.55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Intelligent Bio Solutions Inc. Announces Closing of $2.55 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares and Warrants

Intelligent Bio Solutions (NASDAQ: INBS ) stock is taking a beating on Wednesday after the company announced a proposed public stock offering. The company announced that offering yesterday, and then released details of the offering early this morning.

Why Is Intelligent Bio Solutions (INBS) Stock Down 48% Today?

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced the pricing of its previously announced underwritten public offering of 569,560 shares of common stock and warrants to purchase up to 170,868 shares of its common stock at a combined public offering price of $3.90 per share of common stock and accompanying warrants, for initial gross proceeds of approximately $2.2 million, before underwriting discounts and commissions and offering expenses. The warrants have an exercise price of $3.90 per share, are exercisable immediately and will expire five years following the date of issuance.

Intelligent Bio Solutions Inc. Announces Pricing of $2.2 Million Public Offering

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Intelligent Bio Solutions Inc. Announces Proposed Public Offering

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that on February 27, 2023, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement

- 513(g) submission will allow Intelligent Bio Solutions Inc. to determine the most suitable FDA regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge, as the next step in its expansion strategy into the U.S. -

Intelligent Bio Solutions Inc. files FDA 513(g) regulatory submission for Intelligent Fingerprinting Drug Screening Cartridge

- Second quarter total revenue and government support income increased over 100% year-over-year -

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced a 1-for-20 reverse split of its common stock, effective at 5:00 P.M. Eastern Time today. Beginning on February 10, 2023, the Company's common stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “INBS”, but will trade under the following new CUSIP number: 36151G402.

News for Intelligent Bio Solutions Inc Stock (INBS)